Monday June 26th 2017

Posts Tagged ‘Jugular Veins’

Amanda’s Story of CCSVI treatment and her liberation from MS

Amanda’s Story of CCSVI treatment and her liberation from MS

From YouTube: Video taken during Amanda’s visit to Bulgaria for CCSVI treatment and liberation from MS [Read More]

MS patients tell MPs about life after ‘liberation’

MS patients tell MPs about life after ‘liberation’

A group of patients with multiple sclerosis gathered on Parliament Hill Tuesday to testify how a controversial new treatment has changed their lives, as two Liberal MPs reiterated their call for more research. The patients included Steve Garvie and Lianne Webb, both of whom [Read More]

CCSVI: 20 days after procedure

CCSVI: 20 days after procedure

Hi everyone, here is my update on how I am feeling 20 days after having a venogram and ballooning of stenosed jugular veins. Posted by Mark [Read More]

Latest Topics

Are static and functional balance abilities related in individuals with Multiple Sclerosis? – Pau M, Porta M, Coghe G, Corona F, Pilloni G, Lorefice…

Are static and functional balance abilities related in individuals with Multiple Sclerosis? – Pau M, Porta M, Coghe G, Corona F, Pilloni G, Lorefice…

BACKGROUND: In people with Multiple Sclerosis (pwMS), balance assessment is essential in estimating the risk of falls, [Read More]

CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis

CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis

The European Medicines Agency ’ s Committee for Medicinal Products for Human Use recommends approval of cladribine to [Read More]

Germany’s Merck gets EU backing for oral MS drug

Germany’s Merck gets EU backing for oral MS drug

FRANKFURT (Reuters) - Germany's Merck KGaA has won a key recommendation to become a late entrant to the market for oral [Read More]

New data at EAN show Roche ’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary…

New data at EAN show Roche ’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary…

Roche announced today that new post-hoc analyses from the OCREVUS ™ (ocrelizumab) Phase III clinical trial programme [Read More]

MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation

MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation

/About-the-Society/News/Society-Hosts-Joint-Congressional-Briefing-on-the [Read More]